ArticlePharmacological reports : PR2021

Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study.

Yamini Pathak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.